Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease

Research output: Contribution to journalArticle

Abstract

Objective. Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. Methods. In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. Results. No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. Conclusion. Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.

Original languageEnglish (US)
Pages (from-to)S71-S74
JournalClinical and Experimental Rheumatology
Volume35
StatePublished - 2017

Fingerprint

Myositis
Rheumatic Diseases
Autoantibodies
Dermatomyositis
Breast Neoplasms
Neoplasms
Systemic Scleroderma
Tumor Biomarkers
RNA Polymerase III
Autoimmune Diseases
Case-Control Studies
Prospective Studies

Keywords

  • Autoantibodies
  • Breast cancer
  • Dermatomyositis
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{15482155a022450c917844d7a6f5ada6,
title = "Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease",
abstract = "Objective. Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. Methods. In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. Results. No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. Conclusion. Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.",
keywords = "Autoantibodies, Breast cancer, Dermatomyositis, Systemic sclerosis",
author = "Ami Shah and Antony Rosen and Laura Hummers and May, {Betty J.} and Alpana Kaushiva and Roden, {Richard S} and Armstrong, {Deborah Kay} and Fredrick Wigley and {Casciola Rosen}, {Livia A} and Kala Visvanathan",
year = "2017",
language = "English (US)",
volume = "35",
pages = "S71--S74",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",

}

TY - JOUR

T1 - Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease

AU - Shah, Ami

AU - Rosen, Antony

AU - Hummers, Laura

AU - May, Betty J.

AU - Kaushiva, Alpana

AU - Roden, Richard S

AU - Armstrong, Deborah Kay

AU - Wigley, Fredrick

AU - Casciola Rosen, Livia A

AU - Visvanathan, Kala

PY - 2017

Y1 - 2017

N2 - Objective. Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. Methods. In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. Results. No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. Conclusion. Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.

AB - Objective. Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. Methods. In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. Results. No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. Conclusion. Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.

KW - Autoantibodies

KW - Breast cancer

KW - Dermatomyositis

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85031684125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031684125&partnerID=8YFLogxK

M3 - Article

C2 - 28628466

AN - SCOPUS:85031684125

VL - 35

SP - S71-S74

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

ER -